Shares of Reunion Neuroscience Inc. (TSE:REUN – Get Free Report) traded down 2.7% during mid-day trading on Monday . The stock traded as low as C$1.41 and last traded at C$1.42. 339 shares were traded during mid-day trading, a decline of 97% from the average session volume of 12,447 shares. The stock had previously closed at C$1.46.
Reunion Neuroscience Stock Down 2.7 %
The business’s 50 day simple moving average is C$1.42. The stock has a market capitalization of C$16.64 million, a PE ratio of -0.43 and a beta of 4.20.
About Reunion Neuroscience
Reunion Neuroscience Inc, a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications.
Read More
- Five stocks we like better than Reunion Neuroscience
- What Are the U.K. Market Holidays? How to Invest and Trade
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- 3 Warren Buffett Stocks to Buy Now
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
